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a b s t r a c t
As a series of endeavors to establish suitable measures for the sound development of regenerative
medicine using human stem cell-based products, we studied scientific principles, concepts, and basic
technical elements to ensure the quality and safety of therapeutic products derived from the processing
of human embryonic stem cells (hESCs), taking into consideration scientific and technological advances,
ethics, regulatory rationale, and international trends in human stem cell-derived products. This led to the
development of the Japanese official Notification No. 0907-6, “Guideline on Ensuring the Quality and
Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Human Embryonic Stem
Cells,” issued by Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare of
Japan, on September 7, 2012. The present paper addresses various aspects of products derived from
hESCs, in addition to similar points to consider that are described previously for allogeneic human stem
cell-based products. Major additional points include 1) establishment of hESCs; 2) establishment of
stable and well-characterized cell banks of hESCs and relevant intermediate cell products; 3) concerns
about the presence of undifferentiated cells in final products, which may result in ectopic tissue for-
mation and/or tumorigenesis; and 4) concerns about undesirable immunological reactions caused by the
final products. The ultimate goal of this series of guidelines on regenerative medicine is to provide
suitable medical opportunities as soon as possible to the patients with severe diseases that are difficult to
treat with conventional modalities. If these guidelines are interpreted and employed in a flexible and
meaningful way in this context, they should serve as a useful means to achieve their goals.
© 2015, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Background (chronology and focus of the research)
The details of the present study were described in the previous
papers [1e4]. The present article summarizes points that are
closely related to those presented in the earlier paper.
Regenerative medicine using cell-based products that are
derived from the processing of human cells and tissues is keenly
anticipated in Japan because of difficulties with securing human
organs and tissues in our country. With technology breakthroughs
and research advances, people are increasingly hopeful that med-
ical technology using novel cell-based products will develop into
new therapies.
In Japan, translational research on regenerative medicine is
advancing rapidly. In particular, considerable work has been done
to develop products that make use of human stem cells, i.e., somatic
stem cells such as mesenchymal stem cells, embryonic stem (ES)
cells, and induced pluripotent stem (iPS) cells. Thus, there is an
urgent need to prepare relevant guidelines on the evaluation of
products expected in the near future. Identifying at an early stage of
development the technical, medical, and ethical conditions neces-
sary for the utilization of various types of stem cells is vital for their
rapid application to the treatment of patients.
In the fiscal year 2008, the Japanese Ministry of Health, Labour
and Welfare convened a panel of experts: the “Study Group on
Ensuring the Quality and Safety of Pharmaceuticals and Medical
Devices Derived from the Processing of Human Stem Cells.” The
panel was established as a scientific research project of theMinistry
of Health, Labour and Welfare and has been chaired by Dr. Takao
Hayakawa since its conception.
The objective of the study group is to promote the sound
development of products derived from human stem cells by
investigating scientific and technological advances, ethics, the
regulatory rationale, and international trends regarding human-
stem cell-derived products and to establish and implement
appropriate safety evaluation criteria.
As a result of analyses conducted up to 2009, in accordance with
the Pharmaceutical Affairs Law, and with clinical application of the
products derived from human somatic stem cells, iPS cells, ES cells,
and other relevant cells, the study group concluded that relevant
guidelines should be tailored to specific cell sources and pheno-
types (human autologous versus human allogeneic; somatic stem
cells vs. iPS cells vs. ES cells vs. other cells) to facilitate efficient,
effective, and rational R&D. Points to be considered include but are
not limited to relevant technical details, the manufacturing process,
characterization, quality control, stability evaluation, and the data
necessary to guarantee the safety and efficacy of the products.
With this perspective in mind and with the desire for consis-
tency in scientific principles and concepts, 2 interim reports on
draft guidelines on autologous human somatic stem cell-based
products and autologous human iPS cell-based products were
prepared in 2009 according to Japanese Ministry of Health, Labour
and Welfare Notification No. 0208003. Three other interim reports
of draft guidelines on allogeneic human somatic stem cell-based
products, allogeneic human iPS cell-based products, and human
ES cell-based products were also prepared according to Japanese
Ministry of Health, Labour and Welfare Notification No. 0912006.
These 5 sets of draft guidelines were thoroughly discussed from a
variety of viewpoints. They were then widely circulated among
interested parties as articles in a relevant scientific journal to allow
readers to comment (Hayakawa T., et al.: Regenerative Medicine
[Journal of the Japanese Society for Regenerative Medicine], 9,
116e180 [2010], in Japanese). Thereafter, these articles were
updated and published as 8 articles (Journal of the Japanese Society
for Regenerative Medicine, 10, 86e152 [2011], in Japanese) that
served as the basis for the final draft guidelines. After extensive
discussions with the study group and after public consultation, the
Pharmaceutical and Food Safety Bureau of the Ministry of Health,
Labour and Welfare of Japan issued 5 notifications on September 7,
2012, as described in the previous paper [1].
In the present paper, a continuation of the previous articles
[1e4], we introduce the basic technological requirements for
ensuring the quality and safety of pharmaceuticals and medical
devices derived from human ES cells.
Human ES cells can provide rawmaterial for the production of a
variety of cell types because of their pluripotency, which is greater
than that of somatic stem cells, whose ability to differentiate and
self-replicate is limited. Once effective and efficient differentiation
protocols for the generation of a target cell lineage are established,
human ES cells are expected to stably supply large amounts of cell
substrates for use in cell-based therapies.
Human ES cell-based products were recently evaluated in clin-
ical trials in the USA. However, human ES cells are generated by
destruction of human embryos. Because this approach raises
ethical issues, the generation and use of human ES cells require
careful consideration. To ensure human dignity, the derivation,
distribution, and utilization of human ES cells should adhere to the
“Guidelines for the Derivation and Distribution of Human Embry-
onic Stem Cells” (Japanese Ministry of Education, Culture, Sports
and Technology Notifications No.156 of August 21, 2009, and No. 86
of May 20, 2010) and the “Guidelines for the Utilization of Human
Embryonic Stem Cells” (Japanese Ministry of Education, Culture,
Sports and Technology Notifications No.157 of August 21, 2009, and
No. 87 of May 20, 2010). In these 2 guidelines, basic issues con-
cerning the protection of personal information and protocols for
the derivation and use of human ES cells are defined from the
standpoint of bioethics. According to the guidelines, the derivation
and use of human ES cells from human fertilized embryos is
permitted only for basic research that serves to elucidate human
development/differentiation and tissue regeneration or to develop
new diagnostic methods, approaches to prevention or treatment, or
products intended for medical use.
The goal of basic research that contributes to the development
of “new diagnostic methods, approaches to prevention or treat-
ment, or products intended for medical use” can be interpreted to
mean the development of novel treatments, pharmaceuticals, and
medical devices.
We developed a draft guideline containing the points to
consider for ensuring the quality and safety of cellular products
throughout the process, beginning with the establishment of hu-
man ES cells. The draft guideline by this research team can be
practically applied at present to pharmaceuticals and medical de-
vices manufactured by producing differentiated cells from preex-
isting ES cells. However, in the future, another guideline also needs
to be prepared for pharmaceuticals and medical devices derived
from the processing of newly established human ES cells.
When human ES cells are used a source of cell substrates for the
manufacture of cell- and tissue-based products, data and infor-
mation on their characteristics and competence as raw materials
should be comparable to those described in the “Guidelines on
Ensuring the Quality and Safety of Pharmaceuticals and Medical
Devices Derived from the Processing of Allogeneic Human Cells”
(Notification No. 0912006; from the Director of the Pharmaceutical
and Food Safety Bureau, Ministry of Health, Labour and Welfare of
Japan) in order to ensure the quality and safety of the final products.
This is because the clinical application of products made from both
cell types is allogeneic in nature. Thus, the extent and depth of
evaluation, particularly in terms of adventitious agents and
immunogenicity, should be equal for both cell types.
At present, however, the notifications of the Japanese Ministry
of Education, Culture, Sports, Science and Technology (No. 156 and
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No. 157) and Japanese Ministry of Health, Labour and Welfare (No.
0912006) express different viewpoints, and their recommenda-
tions may therefore be contradictory. The 2 Ministry of Education,
Culture, Sports, Science and Technology notifications focus on the
protection of donors' personal information; the Ministry of Health,
Labour and Welfare notification prioritizes the safety of the raw
materials. It is impractical to require infertility clinics and basic-
research laboratories that generate ES cells from human embryos
to maintain quality control at the level required for pharmaceutical
manufacturing. Thus, the draft guideline does not resolve all of
these issues.
Nevertheless, we thought that it would be helpful to prepare a
draft guideline that outlines points to consider when developing
pharmaceuticals and medical devices derived from newly estab-
lished human ES cells. After receipt of informed consent from do-
nors to use human ES cells as a raw material for cell- and tissue-
based products, the requirements in “4. Chapter II. Manufacturing
methods, 4.1. Rawmaterials andmaterials used inmanufacturing,1.
In vitro fertilized embryos” should be provided, and unlinkable
anonymization should be used. Appropriate measures should be
taken and then justified according to “4. Chapter II. Manufacturing
methods, 4.1. Raw materials and materials used in manufacturing,
3. Establishment of human ES cell lines and human ES cell-derived
differentiated cell lines.” Human ES cells are acceptable as raw
materials for pharmaceuticals or medical devices if a basic study
has taken into consideration both the information required for
pharmaceutical manufacturing and the 2 notifications of the Min-
istry of Education, Culture, Sports, Science and Technology of Japan.
This is indeed a measure to move ES cell-based therapies “from
bench to bedside.” We excluded the use of cloned ES cells from the
draft guideline because many ethical arguments can arise.
Characterization and quality control of raw materials in bi-
ologics cannot be adequately performed because of a material's
indistinct origin and complexity. Likewise, characterization and
quality control of final products cannot be performed adequately
because of a product's limited quantity and complex attributes. To
minimize these problems as much as possible, it is very important
to ensure constancy and robustness in the manufacturing process
for all types of biologics. A key technical element for the proper and
consistent production of biologics is the establishment of a base
camp(s), i.e., the preparation of substrates for production of bi-
ologics at relevant stage(s) in the manufacturing process; these
substrate can be extensively characterized and controlled and are of
stable quality and constant processing of these substrates into the
subsequent intermediate(s) and finally to a desired product is
achievable.
The ideal base camp(s) in the sustainablemanufacture of human
ES cell-based products are cells (banks) and/or intermediate cell
products/lines that have been well characterized, are stable per se
but can propagate under appropriate conditions, can be renewed,
are readily available upon request, and can differentiate properly
into target cells. With regard to the consistent manufacture of safe
products, for certain final products, the proper establishment of
sustainable intermediate cell products/lines (as a sort of a cell bank)
at an intermediate stage of themanufacturing process may bemore
important than emphasizing the characterization, evaluation, or
control of cells at the raw-material stage, which may be difficult. It
is, of course, essential to explain the advantages and appropriate-
ness of such an approach. During establishment of cell lines with
different phenotypes at each stage of differentiation, details of the
cell generation process, such as growth medium, culture condi-
tions, culture period, survival rate, the generation of cell lines, and
methods for isolation, cultivation, and induction of differentiation
of target cells, should be clearly documented and justified, to the
extent possible. To maintain the consistency and stability of
intermediate cell products/lines, critical indicators should be
selected that assess cell attributes such as morphology, cell popu-
lation purity, specific cell markers, karyotypes, proliferation, and
differentiation; acceptance criteria should be set accordingly. In
addition, for the intermediate cell products/lines, indicate the
passage number and/or population doubling limit for meeting the
acceptance criteria.
This draft guideline lists points to consider whenmanufacturing
ES cell-based products from in vitro fertilized embryos and requires
documentation of necessary information. These requirements are
intended to guarantee consistency in quality and to ensure quality
and safetyof thefinal products. It shouldbe emphasized that quality,
safety, and constancy can be ensured via complementary ap-
proaches throughout the manufacturing process, and such mea-
sures shouldbe undertaken in a logical and appropriateway in order
to serve the intended purpose. If the quality, safety, and constancy of
the final product are ensured and scientifically verified, it is possible
to omit certain quality tests and controls over cell banks, interme-
diate cell products, final products, and the manufacturing process
listed in the draft guideline. In this context, if the characterization
and control of ES cell-derived differentiated cells or other inter-
mediate cell products (e.g., intermediate cell lines) as a base camp
and the robustness and consistency of the manufacturing process
are guaranteed, it is not always necessary to follow the guideline,
particularly with regard to upstream processes.
As for ES cell-based products, the presence of undifferentiated
cells in the final product is a major concern from a safety point of
view (e.g., the potential for ectopic tissue formation and tumori-
genesis). This concern is raised from one of the characteristics of ES
cells and is therefore quite difficult to avoid and counteract. Elimi-
nation of the intrinsic characteristics of ES cells is a trade-off, at least
in principle, and is thus considered quite difficult. Accordingly, in
the future, it will be important to have a strategy for the develop-
ment of safer final products that involves improved manufacturing
processes and process controls rather than addressing safety issues
at the ES cell level. Therefore, this draft guideline requires elimi-
nation of contamination with undifferentiated cells at the cell bank
level and intermediate and/or final cell product level by thorough
analysis or efforts to minimize potential contamination via devel-
opment of efficient methods to eliminate or inactivate undifferen-
tiated cells during the cell processing. Furthermore, selection of the
appropriate administration method can minimize the safety risks.
The guideline also explains the importance of technical de-
velopments for the generation and characterization of ES cell-
derived somatic stem cells; these developments may lead to safe,
stable, characteristically well-defined, and appropriate raw mate-
rials. R&D of examination techniques to predict the pluripotency
and differentiation potential of each ES cell lineage and processing
techniques to induce target cells efficiently and properly and to
isolate differentiated cells fromundifferentiated cells during the cell
processing will open up novel opportunities for business.
We included these aspects of ES cells in this draft guideline. The
natural pluripotency and self-renewal ability of ES cells exceeds
those of normal somatic stem cells. Thus, ES cells can differentiate
into a variety of cell types depending on the processing technique.
In clinical applications, the use of ES cell-based products will
involve heterologous transplantation, i.e., administration into a cell
environment that is essentially different from the environment
where the cells exert their natural endogenous function. Points to
consider with respect to these issues are included in this guideline
and are based on Japanese Ministry of Health, Labour and Welfare
Notification No. 0912006.
When interpreting and implementing the present guideline, the
following points should be taken into consideration. The ultimate
goal is to provide patients with new therapies that utilize
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regenerative medicine. The role of the guideline is to present the
scientific principles, concepts, ideas, and technical elements that
will help to achieve the specified goal in the most efficient and
effective manner possible. Because situations, circumstances, and
products will vary, the guideline addresses the points of concern in
a comprehensive manner. Therefore, it is important to identify the
relevant testing parameters and evaluation methods by taking into
consideration, for example, the characteristics of the cells in
question, such as the specific clinical objective and the method of
application. Those that are applicable should be justified and
implemented in an appropriate and flexible manner.
Several points should be kept in mind with respect to the
development of medicinal products for regenerative medicine and
the implementation of this guideline. The desired products are
expected to show a potential as a novel therapeutic method as a
result of relevant proof of concept (POC). Relevant data and/or in-
formation should establish that there are no critical concerns about
product safety that might impede the use of the product in humans
for the first time. Thorough observance of the Declaration of Hel-
sinki, including proper informed consent and right of self-
determination on the part of the patient, is indispensable.
It should be emphasized again that the primary goal of our
endeavor is to offer suitable treatment options as soon as possible to
patients with severe diseases that are difficult to treat with conven-
tional modalities. The present guideline should be useful for this pur-
pose. Therefore, it is important to interpretandemploy theguideline in
a flexible and meaningful way. Stringent observance of the guideline
without taking into account the patients and their specific situation
(which is like putting the cart before the horse) should be avoided.
It is evident that progress in the application of regenerative med-
icine is desirable for maintaining and improving human health. The
development of innovative and revolutionarymedicinal products and
therapeutic techniques should benefit our country as well as the in-
ternational community. Regenerativemedicine is a greatway tomake
apeaceful international contribution thatwill bea legacy formankind.
In this context, the role of the government is to promote clinical
researchand industrialization; regulations andguidelines are adopted
such that we advance towards this common goal in a scientific,
rational, efficient, andeffectivemanner.All those involved, likeplayers
with a common goal in the same arena, should continue to make ef-
forts to deliver to patients revolutionary, cell-based products and
therapeutic techniques as soon as possible.
Guidelines on Ensuring the Quality and Safety of Pharmaceuti-
cals and Medical Devices Derived from the Processing of Human
Embryonic Stem Cells
(Notification No. 0907-6, issued by Pharmaceuticals and Food
Safety Bureau, Ministry of Health, Labour and Welfare of Japan, on
September 7, 2012).
2. Introduction
1. The present guidelines outline basic technical elements for
ensuring the quality and safety of pharmaceuticals and medical
devices derived from the processing of human embryonic stem
(ES) cells. These products are hereafter referred to as human ES
cell-based products or simply as the “desired cell products.”
At present, it is assumed that these guidelines will apply to
pharmaceuticals and medical devices manufactured from
already-existing ES cell-derived differentiated cells. In the future,
when the intention is to manufacture desired cell products using
newly established human ES cells, donors must be thoroughly
briefed about the purpose of establishing the cells, and their
consent must be obtained. Provide the donors with as much
information outlined below in “4. Chapter II. Manufacturing
methods, 4.I. Raw materials and materials used in
manufacturing, 1. In vitro fertilized embryos” as possible and
ensure anonymity of the donors. After that, devise appropriate
measures in accordance with “4. Chapter II. Manufacturing
methods, 4.I. Raw materials and materials used in
manufacturing, 3. Establishment of human ES cell lines and hu-
man ES cell-derived differentiated cell lines” and clearly explain
their appropriateness. There are many types of human ES cell-
based products and methods of clinical application. In addition,
scientific progress in this field is incessant, while expertise and
knowledge are constantly accumulating. Therefore, it is not al-
ways appropriate to consider the present guidelines all-inclusive
and definitive. Consequently, when testing and evaluating each
product, it is necessary to adopt, on a case-by-case basis, a
flexible approach in accordance with the rationale that reflects
the scientific and technological advances at that point in time.
2. The main purpose of evaluating the quality and safety of the
desired cell products before conducting investigational clinical
trials (e.g., at the timeof “clinical trial consultation”) is todetermine
whether there are any quality and/or safety problems that would
obviously hinder initiation of human clinical trials of the humanES
cell-based products in question, whether certain quality attributes
(QA) of the product are understood sufficiently to establish a
relationship between the clinicalfindings and theQA, andwhether
consistency of the QA can be ensured within a definite range.
Simultaneously, it is important toeliminateasmuchaspossibleany
knownrisk factors associatedwithproduct qualityand safetyusing
up-to-date science and technology and to describe the scientific
appropriateness of the results of such an action. The remaining
presumed risk factors should be weighed against the risks associ-
ated with not performing the trials on patients who suffer from
diseases that are serious and life-threatening, or that involve
marked functional impairment or a marked decrease in quality of
life (QOL) resulting from the loss of a certain degree of a physical
function or form, or for which existing therapies have limitations
and do not result in a cure. Furthermore, it is important to entrust
the patient with the right to make a decision after receiving all of
the available information. When applying for approval of investi-
gational clinical trials, applicants submit a provisional nonclinical
data package, which is prepared rationally by taking into account
product aspects and patient aspects including a balance between
the risk of the product versus the risk facing the patient with/
without treatment in question, in order to decide to initiate
investigational clinical trials, on the premise that the data package
submitted at the time of marketing application/registration to
ensure quality and safety will be enriched and developed in line
with the guidelines as the clinical trial progresses.
Finally, applicants are encouraged to discuss with the Pharma-
ceuticals and Medical Devices Agency (PMDA) the type and
extent of data that may be needed to initiate an individual
clinical trial. Because of differences in product origin, target
disease, target patients, application sites, application methods,
and processing methods, there may be numerous variations
among individual data packages; these differences cannot be
definitively clarified in the present guidelines.
3. The items, test methods, criteria, and any other technical re-
quirements described in the present guideline are intended to be
considered, selected, applied, andevaluated to serveeach intended
purpose; theydonotnecessarily require themost stringent level of
interpretation and practice. In accordancewith the purpose of the
present guideline, applicants are encouraged to explain why the
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background, selection, application, and the content and extent of
evaluation are appropriate and scientifically rational.
3. Chapter I. General principles
3.1. Objective
The present guidelines outline basic technical elements for
ensuring the quality and safety of pharmaceuticals and medical
devices derived from the processing of human embryonic stem (ES)
cells. These products are hereafter referred to as human ES cell-
based products or simply as the “desired cell products.”
3.2. Definitions
The definitions of the technical terms used in this guideline are
as follows:
1. “Human embryonic stem cells (ES cells)”: Cells that are collected
from a human embryo or cells that are derived from such cells
through cell division and for cells that are not embryo itself; that
possess the ability to differentiate into endoderm, mesoderm,
and ectoderm; and that maintain the ability to self-renew or a
similar ability.
2. “Processing of cells and tissues”: Any processing of a cell type or
tissue, such as propagation and/or differentiation, production of
a cell line, activation of a cell by pharmaceutical or chemical
treatment, alteration of a biological characteristic, combination
with a noncellular component, and manipulation using genetic
engineering, with the aim of preparing desired cell products to
treat a patient or repair or regenerate tissue.
Isolation of a tissue, homogenization of a tissue, separation of
cells, isolation of a specific cell, treatment with antibiotics,
washing, sterilization by g-irradiation or other methods,
freezing, thawing, and other such procedures that are regarded
as minimal manipulations are not considered “processing.”
3. “Manufacture”: Actions undertaken before the final product (a
human ES cell-based product) is released to the market. This
includes, in addition to the processing of cells and tissues,
minimal manipulations such as isolation of a tissue, homoge-
nization of a tissue, separation of cells, isolation of a specific cell,
treatment with antibiotics, washing, sterilization by g-irradia-
tion or other methods, freezing, thawing, and other procedures
that do not change the original properties of the cells or tissues.
4. “Phenotype”: A morphological or physiological characteristic
that is produced by a certain gene under constant environ-
mental conditions.
5. “HLA typing”: Identification of the type of HLA (human leuko-
cyte antigen), a human primary histocompatibility antigen.
6. “Donor”: A person who donates his/her own cells, which serve
as a raw material for a human ES cell-based product. Persons
who provide sperm and unfertilized eggs.
7. “Transgenic construct”: A construct that contains a vector for
introducing a target gene (a specific gene encoding a desired
protein or RNA) into a target cell, the target gene itself, and the
coding sequences of the elements essential for the expression of
the target gene.
4. Chapter II. Manufacturing methods
Describe all important and relevant information concerning the
manufacturing method, taking into account the items listed below.
This information will help to ensure the quality, safety, and efficacy
of the final products and is important for guaranteeing consistency
in quality from the manufacturing perspective. It should be noted
that quality, safety, and consistency are ensured by mutual com-
plementary measures throughout the manufacturing process. It is
very important that the measures be rational and serve the inten-
ded purpose. It is acceptable to omit a portion of the items listed
below, if the quality, safety, and constancy of the final products can
be established by suitably chosen quality tests, control of the final
or intermediates products, or control of the manufacturing process.
4.1. Raw materials and materials used in manufacturing
1. In vitro fertilized embryos
(1) Source and origin, and justification of their selection
Explain the source and origin of the in vitro fertilized
embryos used to establish the human ES cell line and pro-
vide reasons for selecting these embryos.
(2) Characteristics and eligibility of in vitro embryos used as
raw materials
(i) Features of biological structure and function, selection
criteria
Provide and explain the reasons for selecting the
in vitro embryos used as raw materials with reference
to characteristics of their biological structure and
function, such as morphological characteristics, growth
characteristics, and other suitably chosen and appro-
priate indicators.
(ii) Ethical propriety of donor selection
If a new human ES cell line that is intended for clinical
use is established after publication of the present
guidelines, indicate that the donor was selected in an
appropriate and ethical manner and that the proper
procedure was followed by providing a record of the
review process conducted by the ethical review com-
mittee of the medical facility providing the in vitro
fertilized eggs. For ES cell strains established before
publication of this guideline, it is the responsibility of
the manufacturer of a human ES cell-based product to
demonstrate that selection of the donor was carried out
in an appropriate and ethical manner and that the
proper procedure was followed.
(iii) Donor selection criteria and eligibility
Establish selection criteria and eligibility criteria that
take into consideration age, sex, genetic characteristics,
the medical history, the health condition, test parame-
ters related to any type of infection that may be trans-
mitted, for example, via sampled gametes,
immunological compatibility, and other characteristics
and explain their appropriateness. If donor genomic or
gene analysis is undertaken, it shall be performed in
accordance with “Ethical Guidelines for Analytical
Research on Human Genome/Gene,” issued jointly on
February 8, 2013 (partially revised on November 25,
2014) by the Japanese Ministry of Education, Culture,
Sports, Science and Technology; Ministry of Health, La-
bour and Welfare; and Ministry of Economy, Trade and
Industry.
Infectionwith hepatitis B virus (HBV), hepatitis C virus
(HCV), human immunodeficiency virus (HIV), adult
human T-lymphotropic virus (HTLV), or parvovirus B19
shall be ruled out via physician-donor interviews and
clinical laboratory tests, such as serological tests and
nucleic-acid amplification tests. Infection with cyto-
megalovirus, Epstein-Barr (EB) virus, or West Nile virus
shall also be ruled out, if necessary, via appropriate
clinical laboratory tests.
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In addition, further assess and determine the eligi-
bility of donors by examining the medical history
(mentioned below) of the donor, for example, through
physician-donor interviews, and determinewhether he/
she ever received a blood transfusion or underwent a
transplantation procedure.
 Bacterial infections, such as syphilis (Treponema pal-
lidum), chlamydia, gonorrhea, and tubercle bacillus
 Sepsis or suspected sepsis
 A malignant neoplasm
 Serious metabolic or endocrine diseases
 Collagen and blood diseases
 Hepatic diseases
 Confirmed or suspected transmissible spongiform
encephalopathy (TSE) or other brain disorders
 A specific genetic disease or a family history of a
specific genetic disease
If no link can be made between the name of the
donor and the in vitro embryo, collect as much in-
formation about the donor as possible as described
above in “(iii) Donor selection criteria and eligibility.”
It is acceptable to perform some parts of the afore-
mentioned studies at the stage of ES cell-derived
differentiated cells or at a stage further downstream
in the investigation, after having determined their
appropriateness.
If differentiated cells derived from ES cells are used
as raw materials, collect as much information related
to the above as possible. Alternatively, at a stage (in-
termediate product) where differentiation has pro-
gressed further, it is acceptable to perform the
aforementioned studies and determine their appro-
priateness.
In conclusion, it is important to perform this anal-
ysis to the extent possible at a proper stage (either
raw materials or intermediate products) and to
explain their appropriateness.
(3) Records related to the donor
Retain complete records related to the donor so that any
information necessary to ensure the safety of an in vitro
embryo can be verified. Concrete measures be described to
the extent possible.
(4) Collection of gametes and the preparation, storage, and
transport of in vitro embryos
The collection of gametes that are used to establish a
human ES cell line, preparation of in vitro embryos, and
their storage and transport should be carried out in accor-
dance with items (i) through (viii) below. The establishment
and distribution of a human ES cell line should be conducted
in accordance with “Guideline on the Establishment and
Distribution of Human ES Cells” (Notification No. 156, pub-
lished on August 21, 2009, by the Japanese Ministry of Ed-
ucation, Culture, Sports and Science). Human ES cells are
established (primary culture) using human embryos in vitro.
Do not use ES cells established by preparing a human cloned
embryo and then by using this cloned embryo to establish
the ES cells (secondary establishment). In addition, do not
use entosomatic fertilized embryos.
(i) Eligibility of personnel and medical institutions col-
lecting the samples
When preparing and using human in vitro embryos,
describe the technical requirements for personnel and
medical institutions that collect the male and female
gametes.
(ii) Suitability of the embryo collection method
Describe the method used to prepare the embryos
in vitro. Describe steps taken to select embryos in a
scientifically and ethically appropriate manner.
Determine whether appropriate procedures were fol-
lowed. For gamete collection methods and in vitro
fertilization methods, indicate the suitability of the
equipment and reagents, including the drugs used,
and the measures adopted to prevent microbial
contamination, erroneous sampling (mix-up), and
cross-contamination.
(iii) Informed consent of donors
Describe the details of the informed consent,
including the clinical application, provided by the
donors of the gametes.
(iv) Protection of donor privacy
Indicate the measures adopted to ensure protection
of the donor's privacy.
(v) Tests to ensure donor safety
If tests such as those to confirm the state of the
sampling site need to be performed in order to ensure
the safety of the donor of the gametes, describe the
details of the tests as well as any interventions un-
dertakenwhen the test results indicate that a problem
exists.
(vi) Storage method and measures to prevent erroneous
sampling (mix-up)
If the gametes or in vitro embryos need to be stored
for a definite period of time, set the storage conditions
and storage period and provide the justification.
Describe in detail the measures to be taken to prevent
erroneous sampling (mix-up), referring to “Safety
Control in Infertility Treatments” (dated February 20,
2009, Notification No. 0220001, Equal Employment,
Children and Families Bureau, Japanese Ministry of
Health, Labour and Welfare).
(vii) Transportation methods
If gametes or in vitro embryos need to be trans-
ported, specify the containers used for transport and
the transportation procedure (including temperature
control) and provide the justification.
(viii) Preparation of records and record-keeping procedures
Written records for items (i) through (vii) above
shall be prepared, and record-keeping procedures
should be described in detail. If differentiated cells
that were derived from ES cells are used as raw ma-
terials, collect as much information related to the
above as possible.
2. Rawmaterials other than in vitro embryos, existing ES cells, and
ES cell-derived differentiated cells; materials used in
manufacturing
Describe raw materials other than in vitro embryos, existing
ES cells, and ES cell-derived differentiated cells as well as other
materials used in the manufacturing process; indicate their
appropriateness for their intended use; and, if necessary,
establish their specifications (a set of acceptance criteria and
analytical procedures). Proper quality control of these materials
should be implemented.
When so-called Biological Products or Specific Biological
Products (refer to Articles 2.9 and 2.10 of the Pharmaceutical
Affairs Law) are used as raw materials, use the minimum
amount required and strictly conform to the relevant laws and
regulations, such as “Standards for Biological Raw Materials”
(Notification No. 210, Japanese Ministry of Health, Labour and
Welfare, 2003; a partially revised version was issued on
T. Hayakawa et al. / Regenerative Therapy 2 (2015) 109e122114
September 26, 2014). It is particularly important to adequately
evaluate information related to the inactivation and elimination
of viruses and to specify measures for encouraging retrospective
survey and other studies. The technical requirements described
in this paragraph should be taken into consideration when ES
cells are prepared from in vitro embryos derived from raw
materials (gametes) and when ES cell-derived differentiated
cells and the final products are prepared via directed differen-
tiation from ES cells.
(1) When culturing cells
(i) Indicate the appropriateness of all media components
including such as additives (e.g., serum, growth factors,
and antibiotics), and reagents used for the treatment of
cells and set specifications if necessary. Give consider-
ation to the route of clinical application and other
characteristics of the final product when setting speci-
fications concerning the appropriateness of each
component.
(ii) Take into consideration the following points with
respect to media components:
(a) The ingredients and water used in media should be of
high quality and high biological purity, and their quality
should be controlled using standards equivalent to those
used with pharmaceuticals and pharmaceutical
ingredients.
(b) Provide information on all components of the media as
well as the rationale for their selection and, if necessary,
the quality control and other procedures. However,
widely known and commercially available media prod-
ucts such as DMEM,MCDB, HAM, and RPMI are regarded
as a single raw-material set.
(c) Conduct sterility tests and performance tests on media
that contain all components in order to determine
whether they are suitable as target media. Set specifi-
cations for any other relevant parameters thought to be
controlled in the process and perform proper quality
control.
(iii) Heterologous serum or components derived from het-
erologous or homologous serum shall not be used un-
less they are essential for processes such as cell
activation or cell growth. In particular, for products that
may be used repeatedly, investigate, to the extent
possible, ways to avoid using these serum components.
If the use of serum or other such materials is unavoid-
able, consider the following points and investigateways
to prevent the contamination and the transmission of
bacteria, fungi, viruses, and prions from serum and
other related materials as well as treatment methods
for their elimination, to the extent possible, from the
final product.
(a) Clarify the origin of the serum or other components.
(b) Make strenuous efforts to minimize the risk of prion
infection, e.g., by strictly avoiding the use of serum from
areas or regions with known outbreaks of bovine
spongiform encephalopathy (BSE).
(c) Use these batches of serum only after confirming that
they are not contaminated with viruses or other path-
ogens by conducting appropriate tests to prove the
absence of specific viruses and mycoplasma that origi-
nate in animal species.
(d) Perform appropriate procedures to inactivate and
eliminate bacteria, fungi, and viruses to an extent that
does not affect the activation and growth of the cells. For
example, to avoid the risks associated with latent viral
contamination, perform combinations of heat
treatment, filtration, g-irradiation, and/or ultraviolet
light treatment, if needed.
(e) Preserve and store a portion of the serum used in order
to monitor cultured cells for viral infections, to monitor
onset of viral diseases among the patients, and measure
antigen production in response to a component of the
heterologous serum used.
(iv) When using feeder cells, conduct a quality evaluation
while referring to “Derivation and Characterization of
Cell Substrates Used for the Production of Biotechno-
logical/Biological Products” (Pharmaceutical Notifica-
tion No. 873, issued July 14, 2000, Evaluation and
Licensing Division, Pharmaceutical and Food Safety
Bureau, Japanese Ministry of Health, Labour and Wel-
fare), “Guidelines on Public Health Infection Issues
Accompanying Xenotransplantations” (Notification No.
0709001, issued July 9, 2002, Research and Develop-
ment Division, Health Policy Bureau, Japanese Ministry
of Health, Labour and Welfare), and “Guidelines on
Epithelial Regenerative Therapy Using 3T3J2 Strain or
3T3NIH Strain Cells as Feeder Cells” based on “Guide-
lines on Public Health Infection Issues Accompanying
Xenotransplantations” (Notification No. 0702001, is-
sued July 2, 2004, Research and Development Division,
Health Policy Bureau, Japanese Ministry of Health, La-
bour andWelfare) in order to prevent contamination of
feeder cells and the transmission of bacteria, fungi,
viruses, and prions. Indicate methods for the inactiva-
tion of the cell division potential and conditions such as
cell density when using feeder cells. However, if, for
example, the feeder cells or equivalent cells are being
used in the manufacture of a cell or tissue product that
has already been used clinically and whose character-
istics and microbiological safety have already been
assessed and confirmed, it is possible to omit the virus
tests or parts of other tests by demonstrating the
appropriateness of these cells.
(v) Avoid the use of antibiotics as much as possible.
However, if the use of antibiotics at the initial stages of
processing is deemed indispensable, attempt to
decrease their use at subsequent steps as much as
possible, and clearly indicate the appropriateness of
their use from perspectives such as the scientific
rationale, estimated residual amounts in the final
product, and the effects on the patient. If it has been
determined that an antibiotic can be adequately elim-
inated, its use does not need to be restricted. On the
other hand, if a patient has a history of allergy to the
antibiotic used, in principle, this therapeutic method
should not be used. If there is noway to avoid the use of
antibiotics, administer them very carefully and obtain
informed consent from the patient.
(vi) If growth factors are used, show the appropriate quality
control methods using relevant parameters, such as
purity and potency, for which established acceptance
criteria and assay methods are employed, in order to
guarantee the reproducibility of the cell culture
characteristics.
(vii) For media components and other components that are
used in the processing and that may contaminate the
final product, choose components that do not have any
harmful biological effects.
(2) When combining cells with noncellular components
(i) Quality and safety of noncellular raw materials
If the final product consists of cells and noncellular
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components, such as a matrix, medical materials, scaf-
folds, supportmembranes, fibers, and beads, describe in
detail the quality and safety of the noncellular compo-
nents.
Provide any relevant information concerning the
noncellular raw materials, taking into consideration
their type and characteristics, the form and function in
the final product, and evaluation of their quality, safety,
and efficacy from the standpoint of the presumed
clinical indication. If using materials that are absorbed
by the body, perform the necessary tests on the
degradation products to address safety concerns.
With respect to the tests that should be carried out,
refer to “Basic Views on Biological Tests Necessary for
Regulatory Approval for Manufactured or Imported
Medical Devices” (Notification No. 02013001, issued
February 13, 2003, Evaluation and Licensing Division,
Pharmaceutical and Food Safety Bureau, Japanese
Ministry of Health, Labour and Welfare), describe the
test results, and provide justification for the use of such
raw materials. The use of information obtained from
scientific literature is encouraged.
(ii) Interactions with target cells
Demonstrate the validity of the test methods used
and explain the results obtained for the following 3
items with respect to the interactions between
noncellular components and cells in the final product
and in any intermediate products.
(a) The noncellular components do not have any dele-
terious effects on the function, growth capacity,
activity, or stability of the cells in the final product
required for the presumed clinical indication or the
cells in any intermediate products.
(b) Evaluate to the extent possible any potential in-
teractions between the cells and noncellular com-
ponents, taking into consideration, for example, the
mutation, transformation, and/or dedifferentiation
of the cells in the final product or cells in interme-
diate products.
(c) Show that there is no loss of the expected proper-
ties of the noncellular components for the pre-
sumed clinical indication as a result of any
interactions between the noncellular components
and the cells in the final and intermediate products.
(iii) When using noncellular components to isolate the
desired cell products from the application site
When using noncellular components with the
objective of segregating the cells from the application
site, confirm their usefulness and safety by referring to
items (a) through (e) below.
(a) When immunological segregation is the objective,
describe its level.
(b) Membrane permeability kinetics and the pharma-
cological effects of target physiologically active
substances derived from the cells in the final
product.
(c) Diffusion of nutritional components and excretory
products.
(d) Effects of noncellular components on the area near
the application site.
(e) When a pharmacological effect of a target physio-
logically active substance derived from a desired
cell product is anticipated, and the objective is
segregation of the application site and the desired
cell product and/or undifferentiated cells, confirm
that the cells do not leak out, whichmight result, for
instance, from degradation of noncellular
components.
(3) When cells are subjected to genetic modification
When genes are introduced into cells, provide details for
the following:
(i) For the target gene (the specific gene encoding a
desired protein or RNA): information related to its
structure and origin, the method by which it was ob-
tained, cloning methods, and methods of cell bank
preparation, control, renewal, and other relevant
information.
(ii) Nature of the transgene.
(iii) Structure, biological activity, and properties of the
desired protein or RNA derived from the target gene.
(iv) All raw materials, their properties, and procedures
(transgenic method, origin and properties of the vector,
and method of obtaining the vector used for introduc-
tion of the transgene) needed to produce the transgenic
construct.
(v) Structure and characteristics of the transgene construct.
(vi) Control and preparation methods for cell and virus
banks that are used to prepare vectors and transgenic
constructs.
For manufacturing methods for transgenic cells, refer
to Chapter 2 and other sections of “Guidelines for
Ensuring the Quality and Safety of Gene Therapy Phar-
maceuticals,” which is an appendix in “Concerning
Guidelines for Ensuring the Quality and Safety of Gene
Therapy Pharmaceuticals” (hereafter referred to as
“Gene Therapy Pharmaceutical Guidelines”), published
as Notification No. 1062 by Pharmaceutical Affairs Bu-
reau, Japanese Ministry of Health and Welfare on
November 15, 1995. In addition, state clearly the
appropriateness of the establishment of a cell line in
accordance with the appendix of the same notification.
On the basis of the law (Law No. 97, 2003) imple-
mented to ensure biodiversity by regulating the use
(and other aspects) of genetic recombination-derived
organisms and related organisms, a separate applica-
tion procedure for evaluation will be required when
living organisms, including certain cells, “viruses,” and
“viroids,” are genetically modified. The following cells
are not regarded as living organisms: “human cells” or
“cells that have the ability to differentiate, or differen-
tiated cells that are not viablewhen alone under natural
conditions.”
Regardless of the guidelines mentioned above, if a
gene introduced into cells is used as a reagent in the
manufacturing process and does not contribute either
chemically or functionally contribute to the final prod-
uct, it is acceptable to describe, on the basis of current
knowledge, how the quality and safety of the gene
conform to the intended use.
3. Establishment of human ES cell lines and human ES cell-derived
differentiated cell lines
(1) Establishment of human ES cell lines
Establish human ES cell lines after having determined, to
the best of your ability, the genetic background of the donors
of the male and female gametes used to produce the in vitro
fertilized embryo. Describe the methods used to establish
the ES cells at the stage of the in vitro fertilized embryo and
indicate, to the extent possible, the appropriateness of the
methods. These include the method for obtaining the hu-
man blastocysts, methods for the separation and cultivation
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of the inner cell mass (ICM) from blastocysts, and methods
for the separation and establishment of undifferentiated
cells as well as the media, culture conditions, cultivation
duration, and other characteristics at each step in the pro-
cess used to establish the human ES cell line.
To ensure that the quality of the human ES cell line re-
mains stable and consistent, identify the critical quality at-
tributes of the cells in question by taking into consideration
cell characteristics, such as cell population purity, morpho-
logical features, results of HLA typing, phenotype-specific
markers, karyotype, DNA fingerprinting, cell growth prop-
erties, and pluripotency and set acceptance criteria for the
selected critical quality attributes. In addition, demonstrate
the number of passages or cell divisions within which the
cells maintain their quality in terms of the criteria specified.
Although comprehensive cell characterization is always
desirable, it is recognized that full characterization may be
difficult because there are quantitative and technological
limits on sample analysis. Thus, it is considered acceptable
to perform a limited study to the extent possible.
If information related to infections in donors cannot be
obtained because of donor anonymity or other reasons, rule
out thepresenceofHBV,HCV,HIV, adultHTLV, andparvovirus
B19 in the established human ES cell line by relevant testing.
In addition, rule out infectionwith cytomegalovirus, EB virus,
and West Nile virus, if necessary, by testing. If the genetic
traits of a donor cannot be obtained, analyze the genetic in-
formation on the ES cell line itself to determine if any factors
that are related to genetic diseases are present. Although it is
acceptable to perform these tests at the stage when an ES-
derived differentiated cell line has been established as a cell
substrate fromwhich to manufacture ES cell-based products,
it is preferable to perform the tests on the ES cell line.
(2) Establishment of a human ES cell-derived differentiated cell
line by an institution that uses human ES cells
In some cases, the establishment of a differentiated cell
line derived from human ES cells may be necessary for the
constant manufacture of a safe final product. In other words,
there may be some cases where such an approach is
encouraged as a scientifically rational procedure.When such
a measure is taken, describe the intended use at the facility
and explain the advantages and appropriateness with
respect to the manufacture of the human ES cell-based
product. If a cell line that exhibits a different phenotype is
established in stages, describe the procedure used to
establish each respective cell line, including, for example,
methods of differentiation induction and methods for the
isolation, culture, and establishment of the target cell line as
well as media, culture conditions, culture period, the yield,
and other characteristics and provide justification for the
manufacture of a human ES cell-based product.
To ensure that the quality of the differentiated cell line
remains stable and consistent, identify the critical quality
attributes of the cells in question by taking into consider-
ation various cell characteristics, such as cell population
purity, morphological features, results of HLA typing,
phenotype-specific markers, karyotype, DNA fingerprinting,
cell growth properties, and differentiation potency and set
acceptance criteria for the selected critical quality attributes.
In addition, demonstrate the number of passages or cell
divisions within which the cells maintain their quality in
terms of the criteria specified. Although comprehensive cell
characterization is always desirable, it is recognized that full
characterization may be difficult because there are quanti-
tative and technological limits on sample analysis. Thus, it is
considered acceptable to perform a limited study to the
extent possible.
The conditions that must be fulfilled are identical for
imported ES cell lines and differentiated cell lines derived
from already-existing ES cell strains that were established
before the publication of the relevant official guidelines and
notifications. However, there may be cases where a certain
raw material was used or possibly used, for which the
establishment and maintenance processes are vague or
unclear and thus might not meet the stipulations of the
“Standards for Biological Raw Materials” (Notification No.
210, issued in 2003 by the Japanese Ministry of Health, La-
bour and Welfare; a partially revised version was issued on
September 26, 2014). Because the propriety of using such
cell lines will be reviewed and evaluated on a case-by-case
basis, consultation with the Pharmaceuticals and Medical
Devices Agency (PMDA) is encouraged. (Note: Even when
sufficient infection-related information for the human ES
cell-derived differentiated cell line that will be used cannot
be obtained, the presence of HBV, HCV, HIV, adult HTLV, or
parvovirus B19 in the human ES cell-derived differentiated
cell line should be ruled out by relevant testing. Infection
with cytomegalovirus, EB virus, and/or West Nile virus
should also be ruled out, if necessary, by testing. If the ge-
netic data on a donor cannot be obtained, analyze the ge-
netic information of the ES cell line itself to determine if any
factors related to genetic diseases are present.)
4. Storage and transport of human ES cell lines and human ES cell-
derived differentiated cell lines
For human ES cell lines and human ES cell-derived differen-
tiated cell lines, perform the appropriate stability tests to assess
cell viability, potency, and other characteristics, establish the
storage method and validity period, and make clear their
appropriateness, taking into consideration the duration of
storage and the distribution and storage form. In particular,
when freezing and thawing, determine whether the process of
freezing and thawing has an effect on stability and any other
parameter of the cell line. Evaluate storage during the standard
storage period and confirm the margin of stability to the extent
possible. However, this does not apply when using cells
immediately after their establishment. During transport of a
human ES cell line or human ES cell-derived differentiated cell
line, the containers used for the transport and the trans-
portation procedure (including temperature control) shall be
specified and their appropriateness clearly indicated.
5. Preparation of records and record-keeping procedures
Prepare written records for items 2 through 4 above, and
clearly describe the record-keeping procedures.
4.2. Manufacturing process
Whenmanufacturing human ES cell-based products, describe in
detail the manufacturing method, and verify, to the extent possible,
the appropriateness of the method, using the items listed below, in
order to maintain consistency in the quality of the product.
1. Lot control
Indicate whether a lot control procedure is applied for final
products and intermediate products. If any lot control procedure
is adopted, establish standardized procedures for the makeup
and control of the lot, which may include the lot size, labeling/
numbering, testing method and acceptance criteria.
2. Manufacturing method
Provide an outline of the manufacturing method, from the
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preparation of in vitro embryos from collected gametes to the
establishment of human ES cells, differentiated cells, if any, and
the final product. Describe the technical details of the process
and necessary process control and product quality control.
(1) Tests upon receipt
Establish a battery of tests as well as acceptance criteria
for assessment of eligibility of human ES cells or human ES
cell-derived differentiated cells that will serve as the raw
material, taking into account the nature of the cells and their
intended use. These may include, for example, visual tests,
microscopic examination, and cell viability assays. (Note
that the receipt of an ES cell line at an institution where ES
cell-based products will be manufactured is permitted only
when the clinical use of the said ES cells is officially
permitted by government regulations.)
(2) Establishment of a human ES cell line
Clarify its role in the manufacturing method that the
manufacturer adopted [refer to 4. Chapter II. Manufacturing
methods, 4.I. Raw materials and materials used in
manufacturing, 3. Establishment of human ES cell lines and
human ES cell-derived differentiated cell lines (1)].
(3) Establishment of a human ES cell-derived differentiated cell
line
Clarify its role in the manufacturing method that the
manufacturer adopted, if any [refer to 4. Chapter II.
Manufacturing methods, 4.I. Raw materials and materials
used in manufacturing, 3. Establishment of human ES cell
lines and human ES cell-derived differentiated cell lines (2)].
(4) Establishment of an intermediate cell line derived from
human ES cells
When the manufacturer of a human ES cell-based product
establishes a cell line as an intermediate product (interme-
diate cell line) from an ES cell line or a differentiated cell line
that has been received, explain its advantages and suit-
ability. If a cell line that exhibits a different phenotype is
established in stages, describe the procedure used to
establish each respective cell line, including, for example,
differentiation induction methods and methods for the
isolation, culture, and establishment of the target cell lines
as well as media, culture conditions, culture duration, the
yield, and other characteristics and explain their appropri-
ateness to the best of your ability.
To ensure that the quality of the intermediate cell line re-
mains stable and consistent, identify the critical quality at-
tributes of the cells by taking into consideration various cell
characteristics, such as cell population purity, morphological
features, phenotype-specificmarkers, karyotype, cell growth
properties, and differentiation potency, and set acceptance
criteria for the selected critical quality attributes. In addition,
demonstrate the number of passages or cell divisions within
which the cells maintain their quality in terms of the criteria
specified. Although comprehensive cell characterization is
always desirable, it is recognized that full characterization
may be difficult because there are quantitative and techno-
logical limits on sample analysis. Thus, it is considered
acceptable to perform a limited study to the extent possible.
If establishing a cell bank from the intermediate cell line in
accordance with the criteria described above and utilizing
said cell bank, refer to point (6) below.
(5) Preparation of cells that constitute a principal component
and serve as an active ingredient in the final product
Describe the methods by which cells that serve as an
active ingredient in the final product were prepared from a
human ES cell-derived differentiated cell line or via an in-
termediate cell line derived from a human ES cell line. The
items to be described include induction of differentiation,
isolation, and culture of the desired cells, and the media,
culture conditions, culture duration, the yield, and other
characteristics at each step. Describe the appropriateness of
each method.
(6) Establishment of cell banks
When a cell bank is established at any stage during the
manufacture of human ES cell-based products, describe the
rationale for preparing the cell bank; the methods used to
prepare the cell bank; the characteristics of the cell bank;
and the storage, maintenance, control, and renewalmethods
as well as any other processes and tests performed. Provide
justification for each. Refer to “Derivation and Character-
ization of Cell Substrates Used for the Production of
Biotechnological/Biological Products” (Pharmaceutical
Notification No. 873, issued July 14, 2000, Evaluation and
Licensing Division, Pharmaceutical and Food Safety Bureau,
Japanese Ministry of Health, Labour and Welfare) and other
documents. It is acceptable to omit a portion of the test
items if, for a valid reason, the cells were evaluated properly
at an upstream point in the process.
(7) Measures to prevent erroneous sampling (mix-up) and
cross-contamination during the manufacturing process
It is extremely important to prevent erroneous sampling
and cross-contamination during the manufacturing process
when manufacturing the human ES cell-based products.
Therefore, clearly describe preventive measures in the
process.
(8) Preparation of records and record-keeping procedures
Written records for items (1) through (7) above should be
prepared, and proper record-keeping procedures shall be
clearly described.
3. Characterization of cells that are a principal component and an
active ingredient of the final product
For cells that are a principal component of the final product,
analyze their attributes, such as cell population purity (to con-
trol contamination by undifferentiated cells or nontarget cells),
cell viability, morphological characteristics, growth characteris-
tics, biochemical indicators (markers), immunological markers,
distinctive substances produced by the cells, karyotype, differ-
entiation potency, and other appropriate genotypic and
phenotypic markers. In addition, characterize their biological
functions, if necessary. Furthermore, to evaluate the suitability
of the culture duration and the stability of the cells, use
appropriate cell characteristics to demonstrate that there have
been no unintended changes in cells cultured longer than the
proposed culture period. It is acceptable to perform these
studies preliminarily, using test samples obtained from donors
in place of the real products that will be prepared for a clinical
trial. On the basis of these results, identify the critical cell
characteristics that should be used when applying the product
to the treatment of a patient. Although comprehensive cell
characterization is always desirable, it is not always possible to
characterize the cells fully because there are quantitative and
technological limits on sample analysis. Thus, it is acceptable to
perform a limited study to the extent possible. When cell pro-
cessing, such as growth within the body, is anticipated after a
clinical application, clearly demonstrate the functions expected
by describing the specified criteria with respect to the passage
number or number of cell divisions.
4. The form and packaging of the final product
The form and packaging of the final product shall ensure the
quality of the final product.
5. Storage and transport of the final product
If an intermediate or final products need to be stored and
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transported, the storage procedure and duration, the containers
used for transport, and the transportation procedure (including
temperature control) shall be stated and their suitability clearly
indicated (refer to Chapter III).
6. Consistency of the manufacturing procedure
To assess the consistency of the manufacturing process using
each lot obtained from different production runs, determine
whether they differ significantly with respect to the number of
cells, cell viability, and cell characteristics (such as relevant
markers of phenotype and genotype, functional characteristics,
and the percentage of the desired cells) and from the point of
view of the application method and the intended clinical use of
the product. It is acceptable to use test samples obtained from
donors in place of the products thatwill be prepared for a clinical
trial. Evaluation of intermediate products may provide insight
into the suitability of the cells used as raw materials and the
validity of the manufacturing process up until the intermediate-
product stage and canprovide an appropriate guidepost en route
to thefinal product. Therefore, itmaybe reasonable to adopt such
an approach, where necessary and appropriate.
When the manufacturing process involves long cryopreser-
vation periods or cell cultivation periods, perform sterilization
tests at constant intervals to confirm that sterility has been
maintained.
7. Changes in the manufacturing process
If the manufacturing process is altered at some point during
development, and test results that were obtained using prod-
ucts manufactured before the change in the manufacturing
method are to be used in the application for clinical-trial or
regulatory approval, demonstrate that the products manufac-
tured before and after the change to the manufacturing process
are comparable.
4.3. Quality control of the final product
1. Introduction
The overall quality control strategy for human ES cell-based
products includes specifications (a set of acceptance criteria
and analytical procedures) for the final products, quality control
of rawmaterials for each therapeutic application to each patient,
verification of the suitability of the manufacturing process,
maintenance of consistency, and proper quality control of any
intermediate products.
One of the most critical issues surrounding human ES cell-
based products is contamination of the cells with other undif-
ferentiated cells. It is preferable that the absence of contami-
nation by nontarget undifferentiated cells is verified, as
thoroughly as possible, at the intermediate-product stage.
Specifications will differ among final products, depending on
the type and properties of the desired cells and tissues,
manufacturing methods, the intended clinical use, method of
application, stability, and test methods available. These differ-
ences shall be taken into considerationwhen set the acceptance
criteria and test procedures. In addition, specifications shall be
set and justified from the standpoint of achieving the purpose of
quality control as a whole, by taking into consideration the
mutually complementary relationships among 1) verification of
the suitability of the manufacturing process, 2) the method for
maintaining consistency, and 3) quality control of the raw ma-
terials and intermediate products. The purpose of the assess-
ment at the initiation of clinical trials is to confirm that the
product in question is unlikely to pose significant quality/safety
problems for use in investigational clinical trials. Therefore, it is
possible to set provisional specifications with allowance for
some variation on the basis of the measured values obtained for
a few test specimens, as long as one can explain about the
relationship between the results of clinical tests and the quality
attributes after the clinical trial. However, testing for sterility
and the presence of mycoplasma is essential. It should be noted
that the quality control strategy, including specifications, should
be enriched and developed as the clinical trial progresses.
2. Quality control of the final product
Refer to the general quality control parameters and tests
shown below, set necessary and appropriate specifications for
the final product, and provide the rationale for these specifica-
tions.
Set appropriate acceptance criteria and test procedures for
individual products that do not make up a lot and for products
that do make up a lot because normally each lot is a unit subject
to quality control.
(1) Cell number and cell viability
For cells that are an active ingredient in the final product,
determine the cell number and viability in the final product
or, if needed, in an appropriate intermediate product. At
the beginning of the clinical trial, it is acceptable to set
provisional acceptance criteria that are based on measured
values obtained for a small number of test samples.
(2) Tests of identity
Confirm that the cells are the intended target cells by
assessing important characteristic(s), such as morpholog-
ical characteristics, biochemical markers, immunological
markers, characteristic products, and other appropriate
genotypic or phenotypic features.
(3) Tests of purity
To test the purity of the cell population in a final product,
if necessary, set the test parameters, test methods, and
acceptance criteria for evaluating and controlling
nontarget cells, such as undifferentiated cells, cells that
exhibit abnormal growth, transformed cells, and contami-
nating cells, taking into consideration such parameters as
the origin of the target cells and tissues, the culture con-
ditions, and other parameters of the manufacturing pro-
cess, such as quality control of intermediate products. At
the beginning of the clinical trial, it is acceptable to set
provisional acceptance criteria that are based on measured
values obtained for a small number of test samples.
(4) Tests for cell-derived, undesirable physiologically active
substances
Specify appropriate tests for determining the permissible
dose limits of any possible undesirable physiologically
active substances that may derive from the target cells if
the presence of such substances in the product is presumed
to clearly affect the safety of the patient. At the beginning of
the clinical trial, it is acceptable to set provisional accep-
tance criteria that are based on measured values obtained
for a small number of test samples.
(5) Tests for process-related impurities
For substances that may be present in the final product
as, for example, contaminants, residues, newly generated
products or degradation products; that potentially origi-
nate from raw materials, noncellular components, media
ingredients (including feeder cells), chemical reagents, or
any other process-related materials; and that may have
deleterious effects on quality and safety (for example, al-
bumin derived from fetal calf serum; and antibiotics), it is
necessary to 1) prove that the substance is not present in
the final product by taking into consideration the results of
process evaluations related to the elimination of the sub-
stance or the results of in-process substance control or 2)
T. Hayakawa et al. / Regenerative Therapy 2 (2015) 109e122 119
establish appropriate tests to control permissible levels of
the substance in the final product. When selecting sub-
stances to be tested and setting their acceptance criteria,
their appropriateness should be explained. At the begin-
ning of the clinical trial, it is acceptable to set provisional
acceptance criteria that are based on measured values
obtained for a small number of test samples.
(6) Sterility tests and tests for the absence of mycoplasma
Sterility should be ensured throughout the entire
manufacturing process by evaluating test samples. The
sterility (negative results of tests for common bacteria and
fungi) of the final product should be demonstrated before
its use in patients. Appropriate tests confirming the absence
of mycoplasma should also be performed. A validated
nucleic-acid amplification test can be used. If the results of
the sterility tests and other assays of thefinal product can be
obtained only after the product is administered to the pa-
tient, methods for dealing with the lack of sterility detected
after administration should be established beforehand. In
such cases, demonstrate by testing that the intermediate
products are sterile and that sterility has been strictly
maintained in all processes leading to the final product. If a
product from the same facility and sameprocess has already
been used in patients, its sterility must be confirmed by
testing all patients. If complete closure (hermetic seal) of a
product that is a part of a lot has been ensured, tests on
representative samples are sufficient.When tests need tobe
conducted for each application and if the results of sterility
tests and other assays can be obtained only after adminis-
tration of the product to the patient, the decision to
administer the product will be based on the most recent
data. However, even in such cases, sterility tests and other
assays of the final product shall be conducted.
It is desirable that every effort bemade to avoid the use of
antibiotics in cell culture systems. However, if antibiotics
are used, adopt measures to ensure that they do not influ-
ence the sterility tests.
(7) Endotoxin tests
Perform the endotoxin test, taking into consideration the
impact of the contaminant in the samples. The acceptance
criteria do not necessarily depend on the actual measured
values. Set acceptance criteria by taking into consideration
the safety ranges in the Japanese Pharmacopoeia and/or
any other relevant compendia that are based on a single
dose of the final product. Endotoxin testing can be estab-
lished as an in-process control test. However, in such cases,
specify the criteria, including the validation results, and
provide the justification.
(8) Virus tests
Use titer tests to detect viruses in the intermediate and
final products and confirm that administration of the ES cell-
based products does not adversely affect the patient, when
using cells that are not banked as raw materials or during
manufacturing processes; that are from donors not tested
during the infectionwindow; and inwhichHBV,HCV,HIV, or
HTLV can propagate. If components of biological origin are
used in the manufacturing process, it may be necessary to
test the final product for viruses originating from those
components. However, whenever possible, it is preferable to
determine that there is no contamination by testing or pro-
cess evaluation at the original component stage.
(9) Specific biological tests
In some instances, it will be necessary to consider spe-
cific (quantitative or qualitative) biological testing that
takes into account the cell type, intended clinical use, or
distinctive characteristics of the cells. At the beginning of
the clinical trial, it is acceptable to set provisional accep-
tance criteria that are based on measured values obtained
for a small number of test samples.
(10) Potency assay
If a specific physiologically active substance secreted
from cells or tissues contributes to the clinical efficacy or
effect of a human ES cell-based product, establish test pa-
rameters and/or acceptance criteria for the substance in
order to demonstrate the intended effect. Set acceptance
criteria for potency or quantitation of a gene expression
product secreted from the cells when a transgene has been
introduced. At the beginning of the clinical trial, it is
acceptable to set provisional acceptance criteria that are
based on measured values obtained for a small number of
test samples.
(11) Mechanical compatibility tests
For products that require a certain degree of mechanical
strength, set acceptance criteria for mechanical compati-
bility and durability that take into account the site of
application. At the beginning of the clinical trial, it is
acceptable to set provisional acceptance criteria that are
based on measured values obtained for a small number of
test samples.
5. Chapter III. Stability of human ES cell-based products
Taking into consideration the storage and distribution periods
and the storage form, test the cell viability, potency, and other
characteristics of human ES cell-based products and/or critical in-
termediate products to establish storagemethods and an expiration
date. Provide justification for their suitability. In particular, when
product storage and use involve freezing and thawing, confirm that
the freezing and thawing processes do not affect the stability or
acceptance criteria of the product. Where necessary and possible,
conduct stability studies on products whose manufacturing period
or storage period exceeds normal periods in order to confirm, to the
extent possible, the limits of stability. This doesnot apply if a product
will be used immediately after its production.
If a human ES cell-based product will be transported, the rele-
vant transportation vessels and transportation procedures (such as
thermal management) shall be set and their appropriateness
justified.
6. Chapter IV. Preclinical safety testing of human ES cell-
based products
To the extent that they are scientifically reasonable and tech-
nically possible, relevant animal tests and/or in vitro tests may be
performed in order to address safety concerns associated with a
human ES cell-based product. For noncellular constituents and
process-related impurities, safety concerns should be addressed as
thoroughly as possible by physicochemical analyses not animal
testing. In addition, the presence of undifferentiated cells in the
final product and their potential to cause ectopic tissue formation,
tumorigenicity, or malignant transformation pose important safety
concerns. To reduce the risk of contamination by such cells, conduct
a thorough analysis, to the extent possible, at the cell bank and/or at
the intermediate-product stage; alternatively, develop and utilize
methods that effectively separate, remove, and/or inactivate
contaminating undifferentiated cells during the manufacturing
process. Careful selection of the route of target cell administration
and other parameters may also be the way to minimize safety risks.
Meaningful results are not always obtained when products of
human origin are tested in experimental animals. Thus, there may
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be a scientific rationale for preparing products of animal origin and
testing them in appropriate experimental animals if such a test
system is expected to generate useful information. In such a case,
consider using an animal model that is suitable for the target dis-
ease. (For example, monkeys may be suitable for studies of
neurological diseases, and pigs and/or dogs may be suitable for
studies of cardiovascular diseases.) However, because cells with
characteristics identical to those of cells that constitute a human ES
cell-based product cannot necessarily be obtained from nonhuman
animal species, even if the preparation procedures are the same,
and because a product of animal cell origin manufactured using
identical processes will not necessarily be comparable to a human
cell product, applicants should conduct a feasibility study before
adopting, conducting, and evaluating such tests. When performing
animal experiments using ES cell-based products obtained from
nonhuman animal species, explain why extrapolation to humans is
appropriate. Depending on the case, consider test systems that
employ cells, and clearly explain the suitability of the test system.
Presented below are items and points to consider and to refer to
when confirming preclinical safety of a product. These are provided
as examples for illustration purposes; they are not intended to
prescribe tests for which there is no rational basis. Conduct
necessary and appropriate tests, taking into account the charac-
teristics of the product, such as its intended clinical use, and eval-
uate and discuss the results in a comprehensive manner.
1. For cells expanded beyond the limit set for routine cultivation
(defined by duration of culture, the population doubling level, or
the passage number of the cells), demonstrate that undesirable
alterations other than the intended transformation and
abnormal proliferation of nontarget cells have not occurred.
2. It may be necessary to quantify special physiologically active
substances produced by the cells and tissues and to discuss their
effects when they are administered to patients. In some cases,
significant amounts of active substances including cytokines
and growth factors would be produced by the cells and this may
result in undesirable effects on the patients.
3. From the standpoint of product safety, examine and discuss the
potential effects of the product on a patient's healthy cells and
tissues and the consequences.
4. Investigate and discuss the possibility of ectopic tissue forma-
tion by target cells and/or by contaminating undifferentiated
cells and the potential consequences when the product is
administered to the patients. Discuss this topic in a compre-
hensivemanner, taking into account the type and characteristics
of the product, such as the route of administration, the target
diseases, and the validity of the test system.
5. Investigate and discuss the possibility of undesirable immuno-
logical reactions caused by the product and/or the expression
product of a transgene and the consequences thereof.
6. Using an appropriate animal model or other system, investigate
and discuss the possibility of tumor formation, including benign
tumors and/or malignant transformation, by the final product or
an intermediate product. These studies should be performed
suitably by taking into account the type and characteristics of
the product, the number of cells and route of administration,
mode of application (e.g., cell sheet or cell suspension), cell
engraftment site, target diseases, validity of the tests systems,
and other relevant issues. If there is a possibility of tumorige-
nicity or malignant transformation, provide justification for the
use of the product in question, taking into consideration the
relationship with the anticipated efficacy. (Note: The most
important aspect of a tumorigenicity test is to accurately assess
the tumorigenicity of a final product that will be used in pa-
tients. However, it is conceivable that tumorigenicity will need
to be evaluated using cells from the intermediate product
because the cells comprising the final product cannot be used
for various reasons, such as the impossibility to obtain a suffi-
cient number of cells. Furthermore, in tumorigenicity tests on
animal models, various conditions such as cell dispersion and
cell adhesion to the scaffolding, cell density, and the adminis-
tration site are not necessarily identical to those for the final
product. There are also differences in sensitivity depending on
the species, strain, and immunological state of the animal. The
tumorigenicity of the final product should be evaluated taking
into consideration these circumstances in a comprehensive
manner. The risks to the patient arising from tumorigenicity of
the final product should be rationally evaluated based on the
balance between any risks and the benefits to the patient as a
result of treating the disease.)
7. If an exogenous gene is introduced into certain cells during the
manufacturing process and if it may function or remain as a
residue in the final product, conduct tests in accordance with
“Gene Therapy Pharmaceutical Guidelines.” In particular, if viral
vectors are used, conduct quantitative tests to determine if any
replication-competent viruses are present and provide justifi-
cation for the test method employed. Describe the safety of the
transgene and its products on the basis of their characteristics.
For cells, discuss the possibility of changes in cell growth and the
risk of tumor formation, including benign tumors andmalignant
transformation. Whenever using a vector that can get inserted
into a chromosome, consider the necessity of evaluating
abnormal proliferative characteristics and/or tumorigenicity
and implementing long-term follow-up.
8. Consider conducting rationally designed general toxicological
tests if the product, including an animal-derived product, is
easily obtained and doing so will produce useful information
regarding its clinical application. When conducting general
toxicological tests, refer to “Guidelines for Toxicology Studies on
Pharmaceuticals,” which is an appendix in the document
“Guidelines on Toxicology Studies Required for Regulatory
Approval for the Manufacture or Import of Pharmaceuticals”
(Drug Evaluation Notification 1:24, issued September 11, 1988,
New Drug Division/Evaluation Licensing Division, Pharmaceu-
tical Affairs Bureau, Japanese Ministry of Health and Welfare).
7. Chapter V. Studies supporting the potency or efficacy of
human ES cell-based products
1. A well-designed study on experimental animals and/or cells
should be performed in order to demonstrate, to a scientifically
reasonable and technically possible extent, functional expres-
sion, sustainability of effects, and/or the anticipated clinical ef-
ficacy (proof of concept) of a human ES cell-based product.
2. For transgenic cells, demonstrate the expression efficiency,
sustainability of expression, and biological activity of the
desired products derived from the transgene. Discuss rationale
of the transgene expression products as active ingredients for
anticipated clinical efficacy (proof of concept) of the human ES
cell-based product in question.
3. Where appropriate products derived from the processing of
animal ES cells and/or animal models of a disease are available,
use them to study the potential therapeutic efficacy of the
product.
4. At the beginning of the clinical trial, detailed experimental
studies will not necessarily be required if scientific literature
and/or other information supports the prediction that the po-
tency or efficacy of the product in question will be markedly
superior to that of a different therapeutic method.
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8. Chapter VI. Pharmacokinetics of human ES cell-based
products
1. Pharmacokinetic studies of the internal behavior of transgene
expression products or cells/tissues that constitute the final
products (these studies may include assessment of their ab-
sorption and distribution in experimental animals), should be
performed to an extent that is technically possible and scien-
tifically reasonable extent. Thereby, these experiments are ex-
pected to estimate the survival of cells/tissues administered to
patients and the duration of their effects and to determine
whether the intended efficacy is successfully achieved. (Note:
Testing methods may include histological studies, human Alu
sequences amplification by polymerase chain reaction (Alu-
PCR), magnetic resonance imaging (MRI), positron emission
tomography (PET), single photon emission computed tomogra-
phy (SPECT), and bioimaging.)
2. For human ES cell-based products, clarify, in animal studies, the
rationale for the administration method. In particular, extrapo-
late from animal experiments, the systemic distribution of the
cells after systemic administration and discuss the distribution
from the point of view of clinical usefulness. (Note: Although it
is unclear exactly where the cells adhere with each adminis-
tration route, local administration is presumed to be preferable
to systemic administration. However, if the benefits to patients
can be explained, it is acceptable to use systemic administration.
In any case, an administration method that minimizes the dis-
tribution of an ES cell-based product to organs other than the
target organ would be a rational choice. Even if the cells do
localize to a site other than the intended transplantation site,
this administration method may be used if no adverse effects
result. Arrhythmia caused by osteogenesis of cells that ectopi-
cally localize to the heart is an example of an adverse effect that
can result from ectopic localization.)
3. When the cells or tissues are directly applied or targeted to a
specific site (e.g., tissue) where they are expected to act, clarify
the localization, and discuss the effect of the localization on the
efficacy and safety of the product.
9. Chapter VII. Preliminary analysis of clinical trials
The main purpose of the present guideline is to outline points to
consider when evaluating the quality and safety of human ES cell-
based products, either at the time of application for marketing
authorization or at the beginning of an investigational clinical trial.
In the latter case, it is necessary to determine, while taking into
consideration the clinical usefulness, whether there are any quality
or safety problems that might impede the initiation of human
clinical trials. Thus, quality and nonclinical safety assessments for
the decision to initiate an investigational clinical trial of the product
in question should be considered in reference to the points outlined
below. Any known risk factors associated with product quality and
safety should be eliminated to the extent possible using up-to-date
scientific and technological methods, and the scientific appropri-
ateness should be clearly described. Any remaining risks should be
weighed against the risks associated with not performing the trials
on patients that suffer from diseases that are serious and life-
threatening, that involve marked functional impairment or a
marked decrease in quality of life (QOL) resulting from the loss of a
certain degree of a physical function or form, or for which existing
therapies have limitations and do not result in a cure. Furthermore,
it is necessary to entrust the patient with the right to make a de-
cision after receiving all of the available information, including all
information on identified/presumed risks and anticipated benefits.
1. Target disease.
2. Subjects and patients who should be excluded as participants.
3. Details of the therapy to be performed on the subjects, including
the application of human ES cell-based products and drugs used
concomitantly. (Note: If it is anticipated that drugs to maintain,
enhance, and/or induce the function of the administered or
transplanted cells will be co-administered, verify the intended
activity of the drugs either in vitro or in vivo.)
4. The rationale for conducting the clinical trials in light of existing
therapeutic methods.
5. Plan on explaining the clinical trial to the patients, including the
currently known risks and benefits of the product.
Clinical trials should have an appropriate study design and
clearly specified endpoints. They should be designed in light of the
desired cells/tissues, target disease, and method of application.
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